PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation

Hiroshi Iwata1, Claudia Goettsch1, Amitabh Sharma2,3, Piero Ricchiuto1, Wilson Wen Bin Goh1, Arda Halu1,2, Iwao Yamada1, Hideo Yoshida1, Takuya Hara1, Mei Wei4, Noriyuki Inoue1, Daiju Fukuda1, Alexander Mojcher1, Peter C. Mattson1, Albert-László Barabási2,3, Mark Boothby4, Elena Aikawa1,5, Sasha A. Singh1 & Masanori Aikawa1,2,5

Despite the global impact of macrophage activation in vascular disease, the underlying mechanisms remain obscure. Here we show, with global proteomic analysis of macrophage cell lines treated with either IFNγ or IL-4, that PARP9 and PARP14 regulate macrophage activation. In primary macrophages, PARP9 and PARP14 have opposing roles in macrophage activation. PARP14 silencing induces pro-inflammatory genes and STAT1 phosphorylation in M(IFNγ) cells, whereas it suppresses anti-inflammatory gene expression and STAT6 phosphorylation in M(IL-4) cells. PARP9 silencing suppresses pro-inflammatory genes and STAT1 phosphorylation in M(IFNγ) cells. PARP14 induces ADP-ribosylation of STAT1, which is suppressed by PARP9. Mutations at these ADP-ribosylation sites lead to increased phosphorylation. Network analysis links PARP9–PARP14 with human coronary artery disease. PARP14 deficiency in haematopoietic cells accelerates the development and inflammatory burden of acute and chronic arterial lesions in mice. These findings suggest that PARP9 and PARP14 cross-regulate macrophage activation.
Despite medical advances, the global burden of ischaemic heart disease is increasing. Pro-inflammatory macrophage activation plays key roles in the pathogenesis of many disorders, including arterial disease. Some pathways associated with macrophage activation may contribute to the shared mechanisms of inflammatory diseases, as demonstrated previously. Despite potent therapies such as cholesterol-lowering by statins, substantial residual cardiovascular risk remains, which drives the active search for novel solutions against pro-inflammatory macrophage activation. Dissecting complex and intertwined mechanisms for macrophage activation requires well-defined mechanistic models. The evidence suggests that distinct types of macrophage activation are functionally different in disease pathogenesis, a classification that has helped to assess the heterogeneity of macrophages. For instance, pro-inflammatory and anti-inflammatory phenotypes can oppose one another, develop in response to distinct cytokines, differ in the activating stimuli and produce different cytokines.

A recently proposed nomenclature suggests that each macrophage subpopulation can be called based on a specific stimulator, and that there are distinct classical stimuli and their respective responses—interferon gamma (IFN\(\gamma\)) for pro-inflammatory activation in settings such as atherosclerotic vascular disease and interleukin (IL)-4 for activation that can counter that of M(IFN\(\gamma\)) or M(LPS) macrophages. Hence, we used this paradigm as a starting point to explore novel regulators through global proteomics.

Proteomics screening and bioinformatics in mouse and human data sets found that poly ADP-ribose polymerase 14 (PARP14), also known as ADP-ribosyltransferase diphtheria toxin-like 8 (ARTD8), and PARP9/ARTD9 both increased in M(IFN\(\gamma\)) and decreased in M(IL-4) cells. The network analysis associated these PARP family members with human arterial disease. Sequence similarity to the PARP catalytic domain, which transfers ADP-ribose moieties from NAD to protein acceptors, characterizes the PARP family proteins. The best-characterized member, PARP1/ARTD1, represents poly-ADP-ribosylation enzymes, which processively catalyse long and branching polymers of ADP-ribose additions starting from an initial post-translational modification, commonly of glutamate. Recent evidence also validates proteins that execute mono-ADP-ribosylation as having various functions. PARP14/ARTD8 is an intracellular mono-ADP-ribosyltransferase. Previous reports indicated that PARP14 enhances IL-4-induced gene expression by interacting with the cytokine-induced signal transducer and activator of transcription 6 (STAT6) in B and T cells, thereby functioning as a transcriptional co-activator that may mediate this effect. A recent study reported that PARP14 regulates the stability of tissue factor mRNA in M(LPS) in mouse. Less information exists regarding the molecular function of PARP9/ARTD9. Although PARP9 appears to lack catalytic activity, it increases IFN\(\gamma\)-STAT1 signalling in B-cell lymphoma.

This study employed a multidisciplinary approach, including proteomics, systems biology and cell and molecular biology to explore new mechanisms for modulating the functional profile elicited after macrophage activation. Mouse and human cell lines as well as primary macrophages were used for complementary analyses of PARP14-deficient mouse and human tissues. Ultimately, the analyses led to evidence that expression of PARP14 in haematopoietic cells restrains vascular inflammation in mouse models, which are not solely regulated by either IFN\(\gamma\) or IL-4. Our findings suggest a novel mechanism for regulating the balance of macrophage phenotypes in vascular disease, and potentially other disorders in which macrophage activation has an impact on outcomes.

**Results**

**Proteomics screening for regulators of macrophage activation.** We used the tandem mass tagging (TMT) quantitative proteomics to identify regulators of pro-inflammatory and non-anti-inflammatory activation in mouse RAW264.7 and human THP-1 macrophage cell lines (Supplementary Fig. 1a-c). In this paradigm of macrophage heterogeneity, IFN\(\gamma\) and IL-4 promote distinctive subpopulations. A pilot TMT proteomic study (Supplementary Figs 1d and 2) analysed the changes in the proteomes at 0, 12 and 24 h, and observed the expected increase and decrease in STAT1 in M(IFN\(\gamma\)) and M(IL-4) cells, respectively, as determined by hierarchical cluster analysis (Supplementary Fig. 2). Within this pilot study, we first noted that PARP14 co-clustered with STAT1 in the M(IFN\(\gamma\)) and M(IL-4) data (Supplementary Fig. 2). To ascertain whether any changes in the M(IFN\(\gamma\)) and M(IL-4) proteomes were not because of cell culture conditions, we performed a second, more in-depth study that included an unstimulated macrophage control for both RAW264.7 and THP-1 experiments, and extended the stimulation period to up to 72 h, sampling six time points for a more detailed time-resolved proteomic study (Supplementary Fig. 1d).

In this latter proteomic study, we quantified 5,137 and 5,635 proteins in RAW264.7 and THP-1 cells, respectively, across the three conditions: unstimulated control, IFN\(\gamma\)-stimulated macrophages and IL-4-stimulated macrophages—M(-), M(IFN\(\gamma\)) and M(IL-4), respectively (Fig. 1a and Supplementary Table 1). An overview of the protein intensities across the three conditions revealed that the magnitude of protein abundance levels for each of the IFN\(\gamma\) and IL-4-stimulated RAW264.7 and THP-1 cells were generally higher than those of unstimulated cells (Fig. 1b), indicating that each stimulation promoted changes in protein abundance beyond those due to cell culture conditions alone.

To pursue one class of potential upstream regulators based on protein abundances, we used the following criteria: proteins exhibited (1) an early increase in M(IFN\(\gamma\)) (within 24 h) followed by sustained levels until the later time points (up to 72 h), (2) a decrease in abundance in M(IL-4) and (3) no significant change in M(-). We employed two distinct informatics methods to explore proteins with such behaviours: data filtering (Method 1) and model-based clustering (Method 2; Supplementary Fig. 3). In Method 1, the M(-) data set permitted a subtraction of the background signal at all time points and thus facilitated data filtering (Fig. 1b upper panels and Supplementary Fig. 3b). Three proteins in the data set from mouse RAW264.7 cells and 12 proteins in human THP-1 cells (Fig. 1b lower panels) met the three criteria above. PARP14 emerged from both data sets, and PARP9 appeared in the THP-1 data set (Fig. 1b lower panels). In parallel, Method 2 (Supplementary Fig. 3c) produced 15 and 20 clusters for the RAW264.7 and THP-1 data sets, respectively (Supplementary Fig. 4a). Clusters mined for proteins whose abundances increased in M(IFN\(\gamma\)) but decreased in M(IL-4) with respect to M(-) revealed 490 proteins in the RAW264.7 data set and 414 proteins in THP-1 fulfilling these criteria (Supplementary Fig. 4b and Supplementary Tables 2 and 3). The proteins were short-listed to those with similar time-resolved changes in both in human and mouse data sets, resulting in 38 candidate proteins (Fig. 1c). Both RAW264.7 and THP-1 data sets identified PARP9 and PARP14 (Supplementary Fig. 4a). Collectively, while Method 2 identified PARP9 and PARP14 in RAW264.7 and THP-1 cells, PARP14 was the only common protein that both Methods 1 and 2 identified among over 5,000 proteins in mouse and human data sets.

**The PARP9 and PARP14 network and coronary artery disease.** To understand the influence of PARP9 and PARP14 in a global
interaction network ('interactome') and predict their potential clinical impact in disease mechanisms, we applied a network-based analysis (Supplementary Fig. 5a). Increasing evidence suggests that disease genes are not distributed randomly on the interactome but work together in similar biological modules or pathways\textsuperscript{30,31}. Moreover, gene products (for example, proteins) linked to the same phenotype likely interact with each other and cluster in the same network neighbourhood\textsuperscript{31}. We thus postulated that, if PARP9 or PARP14 influences the network neighbourhood of a disease, its immediate neighbours should be close to a disease module compared with random expectation\textsuperscript{30,31}. Using the random-walk method, we defined a set of genes as a human disease module for each of the cardiovascular and metabolic diseases, and IFN\(\gamma\)-related diseases (see Methods). We then measured the average shortest distance of the immediate neighbours of the PARP9–PARP14 network to each disease module. An interactome mainly describes a set of physical or functional associations between proteins and does not provide functional associations between proteins and does not provide.
cell or tissue specificity. In our study, we thus examined the genes of immediate neighbours reported in macrophages in the public databases.

We included IFNγ-related autoimmune diseases as positive controls, as we used this cytokine to promote pro-inflammatory macrophage activation. The PARP9–PARP14 network is significantly close to systemic lupus erythematosus, dermatomyositis and polymyositis, as expected (Fig. 2). The PARP9–PARP14 network had significantly greater proximity to the human coronary artery disease gene module compared with other cardiovascular and metabolic diseases (Fig. 2 and Supplementary Fig. 5b). The analysis also linked PARP9–PARP14 with osteoporosis. Moreover, we quantified the closeness of PARP9–PARP14 to autoimmune diseases, coronary artery disease and other diseases in the form of the distribution of shortest distances (Supplementary Fig. 5c) and demonstrated a clear separation between the distribution of diseases inside and outside the circle (Fig. 2), indicating an enrichment of shorter distances \((d = 1\) and 2) for IFNγ-related autoimmune diseases (yellow) and coronary artery disease and osteoporosis (blue), compared with other cardiovascular and metabolic diseases (red; Supplementary Fig. 5c). These results may indicate the potential impact of PARP9 and/or PARP14 on the pathogenesis of arterial disease or the onset of its clinical complications.

**In vitro validation in cultured macrophages.** qPCR and western blot analysis validated the proteomic screening data on PARP9 and PARP14. Consistent with the proteomics data (Fig. 3a and Supplementary Fig. 4a), mRNA and protein levels of PARP9 and

---

**Figure 2 | Network analysis links PARP9–PARP14 with coronary artery disease.** The PARP14 (blue)–PARP9 (purple) module consists of the first neighbours of each protein (light blue and orange nodes, respectively). The significance of closeness of the PARP9–PARP14 first neighbours in the interactome (PARP9–PARP14 module) and disease modules compared with random expectation is indicated by \(P\) values. The random expectation was same size-connected components of PARP9–PARP14 module and a disease module drawn randomly from the network. Closeness between PARP9–PARP14 modules and other diseases such as cardiovascular, metabolic and IFNγ-related diseases was evaluated in the network. The inner circle contains significantly close disease modules.
PARP14 increased with IFNγ and decreased by IL-4 (Fig. 3b and Supplementary Fig. 6). At protein levels, PARP14 increased before PARP9 in response to IFNγ (Fig. 3c).

**PARP9 and PARP14 expression in plaque macrophages.** According to the network analysis that linked PARP9 and PARP14 with arterial disease, we performed immunohistochemistry in arterial lesions. Mouse (Fig. 3d, left) and human (Fig. 3d, right) atherosclerotic lesions exhibited PARP9 and PARP14 proteins, while they were less abundant in human carotid arteries with no apparent atherosclerotic changes (Supplementary Fig. 7a). Immunohistochemistry localized PARP9 and PARP14 expression in the majority of macrophages (CD68) of human atherosclerotic plaques, while few if any smooth muscle cells (SMα-actin) and endothelial cells (CD31) stained positively for these PARPs (Supplementary Fig. 7b). These results suggest that macrophages are a major source of PARP9 and PARP14 in human atherosclerotic lesions.

![Figure 3](https://example.com/figure3.png)

**Figure 3 | PARP9 and PARP14 expression in vitro and in vivo.** (a) TMT-derived 0-h-normalized protein abundance profiles for PARP9 and PARP14 from mouse RAW264.7 and human THP-1 M(IFNγ) and M(IL-4) data sets. (b) PARP9 and PARP14 gene expression at 24 h after stimulation (n = 3). (c) PARP9 and PARP14 protein expression visualized by western blot. The time course in the relative protein abundances of PARP9 and PARP14 normalized to β-actin were quantified (graph, n = 3). *P < 0.05 and **P < 0.01, respectively, by Student’s t-test. Error bars indicate s.d. (d) Representative images of PARP9 and PARP14 expression in atherosclerotic plaques from the aorta of an Apoe−/− mouse (n = 3) fed a high-fat diet and from the carotid artery of a human (n = 5). Scale bars, 100 µm.
Pro-inflammatory PARP9 and anti-inflammatory PARP14. A series of subsequent experiments examined whether PARP9 or PARP14 plays a causal role in macrophage activation. Expression levels of gene products typical of the M(IFNγ) phenotype (for example, IL-1β) and in the M(IL-4) phenotype (for example, MRC1) gauged the downstream effects of PARP silencing using small interfering RNA (siRNA) first in macrophage-like cell lines RAW264.7 and THP-1 since the original screening was performed in these cells, and then in human and mouse primary macrophages.

In mouse RAW264.7 cells, PARP14 silencing enhanced the induction of tumour necrosis factor α (TNFα) and inducible nitric oxide synthase (iNOS) by IFNγ, and suppressed the response of MRC1 to IL-4 (Supplementary Fig. 8a). In human THP-1 cells, PARP14 silencing also increased TNFα and IL-1β mRNA induction in response to IFNγ and decreased MRC1 induction by IL-4 (Supplementary Fig. 8b). Increased levels of TNFα and IL-1β proteins in the supernatant of IFNγ-treated THP-1 cells with PARP14 silencing (Supplementary Fig. 8c) supported these data. Silencing of PARP9 suppressed the induction of TNFα, IL-1β and CCL2/MCP-1 mRNA under IFNγ stimulation in THP-1 cells, while MRC1 showed no significant change in IL-4 (Supplementary Fig. 8d).

To obtain unambiguous evidence for the role of PARP9 and PARP14 in macrophage activation, we extended the in vitro validation studies to mouse and human primary macrophages. In human primary macrophages derived from CD14+ peripheral blood mononuclear cells (PBMCs), PARP9 silencing suppressed the expression of TNFα, IL-1β and CCL2/MCP-1 in IFNγ-treated macrophages, but exerted no significant effects on MRC1 induction by IL-4 (Fig. 4a). In contrast, PARP14 silencing accelerated the induction of TNFα, IL-1β and CCL2/MCP-1 by IFNγ, and suppressed MRC1 in IL-4-treated macrophages (Fig. 4a). In mouse bone marrow-derived macrophages (BMDMs), silencing PARP9 and PARP14 exerted the effects similar to those in human primary macrophages (Fig. 4b). Overall, siRNA experiments provided consistent results in macrophage-like cell lines and primary macrophages. Neither PARP14 nor PARP9 showed significant effects on viability, proliferation or apoptosis of mouse primary macrophages (Supplementary Fig. 8e). In addition, enforced expression of PARP14 in THP-1 cells suppressed the induction of TNFα, iNOS, TLR2 and TLR4 in M(IFNγ) (Supplementary Fig. 8f,g). Collectively, these findings indicate that PARP14 suppresses IFNγ-induced responses and augments IL-4 responses in macrophages. In contrast, PARP9 promotes responses to IFNγ.

PARP9 and PARP14 regulate STAT1 and STAT6 activation. Although expression patterns of PARP14 and PARP9 in M(IFNγ) and M(IL-4) were comparable, their respective siRNA experiments yielded opposing results, suggesting the involvement of distinct signalling mechanisms. IFNγ signalling involves activation (phosphorylation) of pro-inflammatory STAT1, while the IL-4 pathway uses anti-inflammatory STAT6 phosphorylation. Immunofluorescence staining demonstrated enhanced intracellular colocalization of PARP14 and STAT1 in IFNγ-treated THP-1 cells compared with unstimulated cells (Supplementary Fig. 9). Moreover, in human primary macrophages derived from CD14+ PBMCs, PARP14 silencing accelerated IFNγ-induced STAT1 phosphorylation and suppressed IL-4-promoted STAT6 phosphorylation (Fig. 4c). PARP14 may suppress pro-inflammatory macrophage activation by modulating the IFNγ–STAT1 axis, and promote the anti-inflammatory IL-4–STAT6 pathway. In contrast, PARP9 silencing decreased STAT1 phosphorylation in IFNγ-treated human macrophages (Fig. 4c), indicating that PARP9 may activate IFNγ–STAT1 signalling and induce pro-inflammatory activation. In addition, siRNA experiments in THP-1 cells that we used for proteomic screening produced similar results on the role of PARP9 and PARP14 on the STAT1 and STAT6 pathways (Supplementary Fig 10a–c). Evidence suggests the participation of STAT3 in immune responses in various contexts. Neither PARP14 nor PARP9 silencing, however, exerted significant effects on STAT3 phosphorylation (Supplementary Fig. 10d,e).

PARP9 and PARP14 interact with each other. The results demonstrated above engendered the hypothesis of regulatory interplay between PARP9 and PARP14. Indeed, PARP9 silencing increased PARP9 mRNA expression in IFNγ-treated human primary macrophages (Fig. 4a) and THP-1 cells (Fig. 5a), while PARP9 silencing increased PARP14 mRNA in these cell types (Figs 4a and 5a). In contrast, enforced expression of PARP14 decreased PARP9 mRNA expression in IFNγ-treated THP-1 cells (Fig. 5a). Previous reports showed that, in B lymphocytes, IL-4 promotes catalytic activity of PARP14, leading to ADP-ribosylation of HDAC2, HDAC3 and p100 (a precursor of p52 that encodes the NF-κB2 protein), and activation of STAT6, thereby inducing its binding to IL-4-responsive gene promoters. Co-immunoprecipitation (IP) revealed a PARP9/PARP14 complex (Fig. 5b) and immunofluorescence demonstrated the enhanced colocalization of PARP9 and PARP14 in THP-1 cells by IFNγ stimulation (Fig. 5c), suggesting that these two molecules interact in macrophages. Recombinant PARP14 protein induced ADP-ribosylation of PARP14 itself, PARP9, STAT1α and STAT6 (Fig. 5d). PARP9 did not promote ADP-ribosylation of either STAT1α or STAT6, which supports a previous report showing that PARP9 lacks catalytic activity. Interestingly, PARP9 suppressed PARP14-induced ADP-ribosylation of STAT1α and STAT6 (Fig. 5d). While the majority of other PAR family members such as PAR1 are poly-ADP-ribosylation enzymes, PAR14 is a mono-ADP-ribosyltransferase. Mass spectrometric analysis determined that Glu657 and Glu705 of STAT1 were mono-ADP-ribosylated by PARP14 (Fig. 6a,b). Glu657 and Glu705 neighbour Tyr701, a functionally critical phosphorylation site of STAT1α (Fig. 6a). Although we could not verify the precise ADP-ribosylation site in the STAT6 peptide, the conserved Glu makes it a plausible candidate (Supplementary Fig. 11). Mass spectrometry further revealed that recombinant PARP9 inhibited PARP14-induced mono-ADP-ribosylation at Glu657 and Glu705 of STAT1α (Fig. 6b, right panels).

The introduction of mutations at Glu657 and Glu705 to prevent ADP-ribosylation helped to investigate the functional relevance of these two sites within STAT1α. Overexpression experiments in mouse BMDMs revealed that mutations at Glu657 and Glu705 enhanced Tyr701 phosphorylation of STAT1α in IFNγ-treated cells as compared with wild-type STAT1α (Fig. 6c). Using the same mutant STAT1α, we have observed a similar response of STAT1α phosphorylation in HEK293 cells (Supplementary Fig. 12a,b). As a functional consequence, mutant STAT1α in mouse BMDMs increased expression of pro-inflammatory iNOS, IL-1β and CCL2/MCP-1 (Fig. 6c). Collectively, these data indicate that PARP14-mediated ADP-ribosylation of Glu657 and Glu705 may control Try701 phosphorylation of STAT1α, a potential mechanism for the interplay between ADP-ribosylation and phosphorylation in macrophage activation.

PARP14 deletion enhances acute arterial lesion development. To provide in vivo evidence that PARP14 participates in arterial lesion formation and macrophage activation, we further used...
**PARP14**

PARP14<sup>−/−</sup> mice. Peritoneal macrophages from PARP14<sup>−/−</sup> or PARP14<sup>+/+</sup> mice enabled the examination of the macrophage phenotype. PARP14<sup>−/−</sup> macrophages expressed higher mRNA and protein levels of iNOS and TNFα under IFNγ stimulation and lower levels of MRC1 and Arg1 mRNAs under IL-4 stimulation compared with PARP14<sup>+/+</sup> cells (Fig. 7a,b). PARP14 deficiency also enhanced phosphorylation of STAT1 induced by IFNγ and decreased STAT6 phosphorylation in IL-4-treated...
peritoneal macrophages (Fig. 7c). BMDMs of PARP14+/+ and PARP14−/− mice supported our results (Supplementary Fig. 13a). These results in PARP14−/− macrophages are consistent with those of in vitro siRNA experiments.

Our network analysis closely linked the PARP9–PARP14 module with coronary artery disease (Fig. 2). To first examine whether PARP14 indeed plays a role in arterial diseases, we used two different models: (1) acute mechanical injury in femoral
Figure 6 | Identification of PARP14-induced ribosylation sites in STAT1. (a) The amino-acid sequence of human STAT1α C terminus. Green amino acids indicate ribosylated peptides; confirmed ribosylation sites are underlined. STAT1 is phosphorylated at indicated tyrosine (red). (b) Left panels) MS/MS spectra for the mono-ADP-ribosylated peptides and corresponding unmodified forms. ADP-ribose fragments are annotated in green. *, ribosylation site; m, oxidized methionine. The grey circles indicate background or undetermined ions. (Right panels) MS1-based quantification of PARP9 inhibition of PARP14-mediated STAT1α ribosylation at E657 (upper panel) and E705 (lower panel), respectively. (c) Effects of mutated amino acids at E657 and E705 in STAT1 (ribosylation sites for PARP14) on its Tyr701 phosphorylation and pro-inflammatory gene expression in mouse bone marrow-derived macrophages (n = 4). *P < 0.05 and **P < 0.01, respectively, by Student’s t-test. Error bars indicate s.d.
Figure 7 | Role of haematopoietic PARP14 in acute arterial lesion formation in mice. (a-c) Cultured peritoneal macrophages derived from PARP14−/− and PARP14+/+ mice. (a) IFNγ and IL-4 pathway gene expression profiles (n = 3). (b) Secretion of inflammatory factors into culture media (n = 3). (c) Western blot and corresponding densitometry quantification of phosphorylated STAT1 and STAT6. Each data point is the average of triplicate samples per donor (n = 3). (d) Left: representative images of haematoxylin and eosin (H&E; top) and Mac3 (bottom) staining. Scale bars, 100 μm. Right: quantification of lesion formation in mechanically injured femoral arteries of PARP14−/− and PARP14+/+ mice. Mac3 staining represents macrophage accumulation (n = 4–5). (e) LCM of the neointima followed by gene expression analysis (n = 4). (f) Flow cytometry analysis of splenic CD11b+Ly6G– monocytes after induction of mechanically injured femoral arteries of PARP14+/+ and PARP14−/− mice (n = 3). (g) Representative H&E staining images and quantification of neointima formation in mechanically injured femoral arteries after bone marrow transplantation (BMT) PARP14+/+ → +/+ and PARP14−/− → +/+ mice (n = 6). Scale bars, 100 μm. * P < 0.05 and **P < 0.01, respectively, by Student’s t-test. Error bars indicate s.d.
arteries of PARP14−/− mice and (2) acute injury in mice that underwent bone marrow transplantation from PARP14−/− mice. In a model of acute arterial responses due to wire-mediated mechanical injury, PARP14 deficiency enhanced neointima formation (Fig. 7d, top panels) and increased macrophage accumulation (Fig. 7d, bottom panels). Laser capture microdissection (LCM) of the intima of injured femoral arteries followed by real-time PCR demonstrated that PARP14 deficiency increased the levels of TNFα and iNOS mRNA and decreased Arg1 mRNA (Fig. 7e). The spleen is a reservoir of monocytes/macrophages that releases these cells in response to an event in remote organs37. Flow cytometry of splenic cells revealed that, in CD11b+ Ly6G− monocytes/macrophages (Supplementary Fig. 13b), acute arterial injury increased the Ly6Chigh population (PARP14+/+ →−/− mice), which was further expanded by PARP14 deficiency (Fig. 7f and Supplementary Fig. 13c).

To examine the relative contribution of PARP14 in the haematopoietic lineage to the lesion development after acute mechanical injury, we performed bone marrow transplantation from PARP14+/+ and PARP14−/− mice. Lethally irradiated PARP14−/− bone marrow (BMTPARP14−/−→−/+ mice), neointima formation after injury was accelerated, as compared with control PARP14−/−/+ mice whose bone marrow was reconstituted by PARP14+/+ cells (BMTPARP14+/+-/+ mice; Fig. 7g). These results indicate that PARP14 derived from the haematopoietic cell lineage, the majority of which are macrophages in the neointima, plays an important role in the development of arterial disease.

**Haematopoietic PARP14 deficiency enhances atherogenesis.** To further examine the role of PARP14 in chronic arterial diseases, we used high-fat/high-cholesterol-fed low-density lipoprotein receptor-deficient (LDLR−/−) mice, an established model of atherosclerosis. Lethally irradiated LDLR−/− mice whose bone marrow was reconstituted with PARP14−/− cells (BMTPARP14−/−→LDLR−/−) or PARP14+/+ cells (BMTPARP14+/+-LDLR−/−) underwent high-fat/high-cholesterol feeding to develop chronic atherosclerotic plaques. Sixteen weeks after the initiation of an atherogenic diet, BMTPARP14−/−→LDLR−/− mice exhibited more plaque formation and macrophage accumulation in the aortic root compared with BMTPARP14+/+→LDLR−/− mice (Fig. 8a). The aorta of BMTPARP14−/−→LDLR−/− contained higher expression levels of the pro-inflammatory TNFα and CCL2/MCP-1, while MRC1 expression tended to be lower (Fig. 8b). BMT from PARP14−/− mice also increased PARP9 expression in the aorta (Fig. 8b). These results are consistent with other in vitro and in vivo data that we have reported in the present study. Taken together, these findings indicate that PARP14 derived from the haematopoietic lineage, the majority of which are macrophages in arterial lesions, plays a protective role against the development of arterial diseases, which verifies our prediction by network analysis.

**Macrophage-rich human atheroma and PARP9.** Seeking additional in vivo evidence for the potential role of PARP9 and PARP14 in arterial disease involved immunohistochemical analysis of human carotid atherosclerotic plaques surgically removed by endarterectomy. PARP9 and PARP14 signals were predominantly localized in plaque macrophages, as indicated by the overlapping CD68-positive signal (Fig. 8c and Supplementary Fig. 14). Quantitative analysis demonstrated that more macrophages were immunoreactive for PARP9 in macrophage-rich plaques than in macrophage-poor plaques, while there was no significant difference in PARP14-positive macrophages (Fig. 8c).

While some macrophages in the human plaques coexpressed PARP9 and PARP14, other cells stained positively for either PARP9 or PARP14 alone (Supplementary Fig. 14). These lines of in vivo evidence indicate that macrophages in arterial lesions are heterogeneous, which may reflect diverse levels of pro-inflammatory activation in individual cells.

**Single-cell analysis of primary human macrophages.** The diversity in expression patterns of PARP9 and PARP14 in human plaques necessitated the additional assessment of macrophage subpopulations using single-cell gene expression profiling of PBMC-derived human CD14-positive macrophages. Examined cell numbers were 86 in M(-) and 84 in M(IFNγ) of Donor 1, 93 in M(-) and 86 in M(IFNγ) of Donor 2 and 90 in M(-) and 81 in M(IFNγ) of Donor3, respectively. Our examination investigated whether responses of human primary macrophages towards IFNγ stimulation are heterogeneous. Comparing average levels of readouts (for example, inflammation-related factors) in the entire group of cells by qPCR cannot address this question. A workflow of single-cell gene profiling is shown in Supplementary Fig. 15a.

The expression patterns of 91 target genes (Supplementary Table 4) in M(-) (n = 268) and M(IFNγ) (n = 252; n = 520 in total) derived from the three different donors. All cells were evaluated against each other based on their gene expression dissimilarity (Manhattan distance, http://www.nist.gov/dads/). We present the distance matrix as a distance-based graph. By combining the two conditions—M(-) and M(IFNγ)—across three donors (six conditions in total), M(-) cells (green) and M(IFNγ) (red) are clearly segregated, forming distinct clusters (Fig. 9a). However, there are ‘trails’ of M(IFNγ) that appear in the M(-) cluster, suggesting potential heterogeneity. Although this may be attributable to donor-to-donor variations, similar patterns were observed within individual donors as well (Supplementary Fig. 15b). As we are particularly interested in the expression profiles of PARP9 and PARP14, we examined variations/correlations in their expression levels in M(-) and M(IFNγ) human primary macrophages. In both phenotypes, PARP9 and PARP14 were correlated. However, M(-) cells showed lower levels of variation for PARP9 and PARP14 mRNA expression than did M(IFNγ) (Supplementary Fig. 15c). These findings suggest that the ‘IFNγ-polarized’ human primary macrophages are heterogeneous.

It is possible to subdivide the cells into subpopulations based on expression profile similarity (Fig. 9b). Using Ward’s linkage, we observed the following three subpopulations: M(IFNγ) (Cluster 1), M(-) (Cluster 2) and Mixed (Cluster 3). It is important to note that these populations are not homogeneous and can be further divided into at least two subgroups (Groups 1 and 2, Fig. 9b) in human primary M(IFNγ) (Cluster 1). Both PARP9 and PARP14 were significantly higher in Group 2 than in Group1. Considering the possible importance of PARP9 and PARP14 in the macrophage phenotype, we subsequently examined the genes related to macrophage functions in these two Groups 1 and 2. The potent matrix-degrading enzyme MMP-9 and the pattern recognition receptors CD36, TLR2 and TLR4 were higher in Group2, indicating that this subpopulation, which is associated with increased PARP9 and PARP14 expression, may possess a more pro-inflammatory phenotype (Fig. 9c). In our in vitro and in vivo experiments, RNA silencing or genetic deletion of PARP14 enhanced pro-inflammatory responses in IFNγ-stimulated macrophages. In the single-cell analysis, average levels of MMP-9 and TLR4 mRNA expression were also higher in IFNγ-stimulated macrophages treated with PARP14 siRNA (Supplementary Fig. 15d). However, their responses to PARP14 were heterogeneous.
**Figure 8 | Haematopoietic PARP14 in mouse atheromata and PARP9–PARP14 expression in human plaques.** (a) Representative image and quantification of aortic root lesion formation and CD68+ macrophage accumulation (green, Alexa 488) in high-fat and high-cholesterol diet-fed LDLR−/− mice whose bone marrow was reconstituted by PARP14+− mice (BMT PARP14+/−→LDLR−/− mice, n = 5), compared with LDLR−/− mice with PARP14+/+ bone marrow (BMT PARP14+/+→LDLR−/− mice, n = 6–7). Scale bars, 100 μm. (b) mRNA expression of the aorta from a. n = 6–8. (c) Immunofluorescence staining of PARP14 and PARP9 proteins (green, Alexa 488) in human carotid plaques. CD68 (red, Alexa 594). Nuclei (blue, 4,6-diamidino-2-phenylindole, DAPI). Scale bars, 100 μm; insets, 10 μm (n = 5). Prevalence of PARP14+ or PARP9+ macrophages in macrophage-poor versus macrophage-rich plaques. *P<0.05 and **P<0.01, respectively, by Student’s t-test. Error bars indicate s.d.
Figure 9 | Single-cell gene expression analysis of CD14+ macrophages. (a) Heterogeneity in IFNγ-stimulated compared with unstimulated cells in combined all donor cells (n = 520). (b) Similarity map of cells from all donors/conditions reveals three subpopulations; IFNγ-stimulated cells (Cluster 1), unstimulated cells (Cluster 2) and mixed populations (Cluster 3). Cluster 1 inset—there are two further subpopulations within IFNγ-stimulated cells, such as Groups 1 and 2. (c) The relative expression data for genes related to macrophage function are compared between Groups 1 and 2 (n = 112 and n = 63, respectively). (d) Similarity maps of 91 genes examined. (e) Gene similarity map of PARP9/14, STAT, JAK and IRF genes based on analysis with all cells from all donors and conditions. *P<0.05 and **P<0.01, respectively, by Student’s t-test. Error bars indicate s.d.
The gene expression correlation matrix of genes across all cells (Fig. 9d) demonstrates that both PARP9 and PARP14 are closely associated with genes known to participate in IFNγ signalling (for example, JAK1, JAK2, STAT1, STAT6, IRF1 and IRF5). This correlation is highly specific to these genes, and does not extend to other genes that we tested in this assay. Genes that are not correlated with PARP9 and PARP14, among all 91 genes tested, include JAK3, a mediator of IL-4 signalling (Fig. 9e). Of interest, these correlations are further enhanced in M(IFNγ) compared with M(-) (Supplementary Fig. 15e).

Discussion

The present study provides new evidence that PARP9 and PARP14 regulate macrophage activation. The specific novel findings demonstrated in this report include the following: (1) PARP9 promotes IFNγ-induced responses in mouse and human macrophages; (2) PARP14 suppresses IFNγ responses in mouse and human macrophages; (3) PARP14 induces IL-4-triggered responses in mouse and human macrophages; (4) PARP9 and PARP14 appear to have physical and functional interactions; (5) PARP9 and PARP14 closely interact with components of IFNγ signalling in macrophages; (6) PARP14-induced mono-ADP-ribosylation of STAT1 inhibits its phosphorylation; (7) the PARP9 and PARP14 interactomes have significant proximity to the coronary artery disease module; (8) PARP14 deficiency indeed accelerates macrophage activation and lesion development in mouse models of acute and chronic arterial diseases; (9) PARP14 in the haematopoietic lineage exerts protective effects against arterial diseases; and (10) single-cell analysis revealed that IFNγ-stimulated human primary macrophages derived from CD14+ PBMC contain subpopulations, in which PARP9 and PARP14 are closely associated with genes of IFNγ signalling. Our findings provide insight into new mechanisms for macrophage activation that play a critical role in the pathogenesis of inflammatory arterial diseases, a global health burden.

We aimed to establish the unambiguous evidence for the role of PARP9 and PARP14 in macrophage activation using in vitro and in vivo studies. In this study, M(IFNγ) and M(IL-4) as two multidimensional models of macrophage heterogeneity were used in an unbiased proteomics approach. We then validated our key results on the functionality of PARP9 and PARP14 in mouse and human primary macrophages. Bioinformatic analysis of single-cell gene profiling in human primary macrophages revealed close links among PARP9, PARP14 and IFNγ pathway-related molecules (for example, JAK1, JAK2, STAT1 and STAT6), suggesting that these PARP family members contribute critically to the process of M(IFNγ) activation.

We took advantage of the availability of a well-characterized paradigm of macrophage heterogeneity. The balance of diverse macrophage phenotypes (for example, pro-inflammatory versus anti-inflammatory subsets) may regulate normal homeostasis and disease mechanisms. Effective and safe anti-inflammatory therapies may require the fine-tuning of the imbalance of diverse macrophage phenotypes (for example, suppressing excessively activated pro-inflammatory macrophages without compromising protective functions or with enhancing anti-inflammatory activation). Our major goal was to identify molecules or pathways that may regulate the delicate balance of macrophage heterogeneity using global proteomics of M(IFNγ) and M(IL-4). We thus used stringent criteria to choose proteins that increased during M(IFNγ) activation and decreased in M(IL-4). Our in vitro experiments indicate that the interplay between PARP9 and PARP14 may indeed regulate the M(IFNγ)/M(IL-4) balance. We further validated the in vitro results in human arterial lesions and mouse models of arterial disorders, neither of which is solely regulated by IFNγ or IL-4, to provide clinically translatable evidence. Human and mouse atherosclerotic plaque macrophages express PARP9 and PARP14. We identified four macrophage subpopulations in human lesions: PARP9+/PARP14+; PARP9+/PARP14−; PARP9−/PARP14+; and PARP9−/PARP14−. Single-cell gene expression analysis further revealed that IFNγ-stimulated human primary macrophages—M(IFNγ)—are heterogeneous, which may support an emerging concept of the multidimensional model of macrophage activation. In addition, subpopulations within these IFNγ-stimulated cells may have different functions, as shown by associations with MMP-9, CD36, TLR2 and TLR4. Future studies addressing the functional significance of the heterogeneity in human primary macrophages may lead to the development of personalized medical solutions.

To explore the evidence for the anti-atherogenic role of PARP14 beyond in vitro assays, we used PARP14−/− mice. Genetic deletion of PARP14 indeed promoted macrophage activation and accumulation in the intima of mechanically injured arteries, offering in vivo proof of concept. Moreover, significant acceleration of acute arterial lesion formation and chronic atherosclerosis was observed in the mice reconstituted with PARP14−/− bone marrow. These findings suggest that haematopoietic PARP14 plays a central role in arterial disease.

Our study further revealed the new biology for understudied members of the PARP family—PARP9 and PARP14. ADP-ribosylation assays demonstrated that PARP14 has the ability to mono-ADP-ribosylate STAT1 and mass spectrometric analysis identified two ADP-ribosylation sites proximal to its key phosphorylation site. Interestingly, PARP9 suppresses PARP14-dependent mono-ADP-ribosylation of STAT1. Furthermore, mutations of STAT1ζ ribosylation sites for PARP14 enhanced its phosphorylation and pro-inflammatory gene expression in macrophages. The interplay of PARP9 and PARP14 in STAT1ζ ADP-ribosylation and phosphorylation may in part explain why PARP9 and PARP14 exert opposing effects on IFNγ- and IL-4-induced macrophage activation. Supplementary Fig. 16 demonstrates an overview of regulatory mechanisms for the IFNγ-STAT1 and IL-4-STAT6 pathways by PARP9 and PARP14.

In this study, unbiased global proteomics and bioinformatics of IFNγ- and IL-4-treated macrophages implicated PARP9 and PARP14 in novel mechanisms of macrophage activation. The subsequent network-based prediction of the close relationship between the macrophage PARP9–PARP14 module and human coronary artery disease genes supported the premise that our proteomics screen would effectively identify regulators of macrophage activation in the context of cardiovascular diseases. The approach was then followed by a series of in vitro and in vivo analyses on mouse and human cells/tissues that demonstrated the novel concept that PARP9 promotes and PARP14 suppresses IFNγ-induced activation of macrophages (Supplementary Fig. 16). The present study also represents our strategy of target discovery research assisted by global proteomics screening and subsequent validation studies (Supplementary Fig. 17). Collectively, our discoveries indicate that inhibition of PARP9 and/or activation of PARP14 may attenuate macrophage-mediated vascular diseases, and also provide new insight into the development of effective therapies for other inflammatory disorders.

Methods

Cell stimuli for cell culture and TMT sample preparation. In this study, we used mouse and human IFNγ 10 ng ml−1 and IL-4 10 ng ml−1 (R&D systems) as stimuli for macrophage activation, respectively. The murine monocye/macrophage cell line RAW264.7 was obtained from American Type Culture Collection (ATCC, TIB-71, Rockville, MD) and maintained in 10% fetal bovine serum (FBS, Life Technologies) containing DMEM (Sigma) supplemented with penicillin and streptomycin (Corning) at 37 °C in humidified 5% CO2. Before stimuli
scan range of 380–2,000 by 5 min of 95% Solvent B. All reagents were HPLC-grade. For TMT analysis, dissociation (HCD, collision energy 40%, isolation width 3 fixed at 120 μl for 10 or 30 min, followed by 5 min of 95% Solvent B. All reagents were HPLC-grade. For TMT analysis, LTQ-Orbitrap was set to 120 K resolution and the top 20 precursor ions (within a scan range of 380–2,000 m/z) were subjected to higher-energy collision-induced dissociation (HCD, collision energy 40%, isolation width 3 m/z, dynamic exclusion enabled, starting m/z fixed at 120 m/z and resolution set to 30 K) for peptide sequencing (MS/MS). The Q Exactive was set to 140 K resolution with a top 10 precursor selection method (scan range of 380–1,500 m/z). HCD was set to a stepped normalized collision energy of 25 ± 10%, isolation width of 1.6 m/z, dynamic exclusion, and resolution set to 5 K for MS/MS. Tryptic peptide candidates were screened in the MS/MS scan by the m6 peak of 348.1 (refs 40, 41). Unmodified forms were calculated by subtracting the mass of the ADP-ribose (541.06 Da) from the observed precursor. Modified and unmodified m/z values and corresponding retention time windows were submitted to a inclusion list and analysed in using the data-independent acquisition module of the Q Exactive (R = 35 K).

The MS/MS data were queried against the mouse or human UniProt database (downloaded on 27 March 2012) using the SEQUEST search algorithm via the Proteome Discoverer (PD) Package (version 1.3, Thermo Scientific)42, using a 10 ppm mass error tolerance in the MS1 signal and a 0.01 peptide sequence tolerances for the HCD. Methionine oxidation was set as a variable modification, and carbamidomethylation of cysteine residues and 6-plex TMT tags (Thermo Scientific) were set as fixed modifications. The peptide false discovery rate (FDR) was calculated using Percolator provided by PD: the FDR was determined by the number of MS/MS spectral hits when searched against the reverse decay mouse or human database43,44. The proteins were filtered based on a 1% FDR. Peptides assigned to a given protein group, and not present in any other protein group, were considered as unique. Consequently, each protein group is represented by a single master protein (PD Grouping feature). Master proteins with two or more unique peptides were used for TMT reporter ratio quantification (Supplementary Table 2 contains a summary of peptides and peptide-spectrum matches (PSMs) for PARP9 and PARP14). Ribosylation spectra were manually annotated40,41.

Proteomics normalization and filtering strategy. For each PSM the TMT ion channel intensities were normalized to the time-zero channel (reference normalization, for example, \( R_i = x_i \), where \( i = 1, 2, \ldots, 6 \) and \( x_i \) is the time-zero abundance). The protein abundance data was then translated by calculating the median of its corresponding PSM ratio45. To extract the proteins that increase in IFNγ-stimulated (M(IFNγ)) but decrease in IL-4-stimulated condition (M(IL-4)), we applied a simple filtering logic that exploited the available unstimulated control data set. In this study, unstimulated control, M(0), serves as a control for the biological signal owing to the cell culture condition; that is, protein traces M(IFNγ) and M(IL-4) that exceed the edges of the baseline are more likely to be bona fide IFNγ- and IL-4-specific responses (Supplementary Fig. 3b). Protein profiles whose abundances surpassed the baseline, which was defined as maximum relative abundance at 8 h of M(0) (+ 0.13, log10 of relative abundance), after supplement of IFNγ and IL-4, respectively, were considered as potential PARP14–PARP9 interactome identified by the shortest-path distance distribution with the same module size (Wilcoxon test and Benjamini–Hochberg correction for multiple testing). Finally, we verified that the module size does not affect the significance of the P values for the Coronary Heart Disease and Atelectasis modules by recalculating the random distances by reducing the module size to the top 35 genes from random walk.

Mouse peritrophic macromolecules. Four days after intraperitoneal injection of 2.5–3 ml of 4% thiglycollate (Sigma-Fluka), peritrophic macromolecules were obtained by injecting 3 ml of ice-cold PBS into the peritoneal cavity using 25 G needle, followed by collection of the fluid using 25 G needle. In all, 5 × 10^6 cells were obtained per well in 24-well plate with 3 ml PBS. The Nonadherent cells were discarded after 16 h. After washing with PBS, cells were incubated with IFNγ 10 ng ml⁻¹ and IL-4 10 ng ml⁻¹ for 24 h until harvesting.
### Immunohistochemistry and immunofluorescence

Samples were cut into 7 μm thin slices, and cryo-sections were fixed in acetone. After blocking in 4% appropriate serum, sections were incubated with primary antibodies (Mac3 (1:200, BD Pharmingen), PARP14 (1:50, HPA01206, Sigma-Aldrich), PARP9 (600 cells per sample). The quantification of immunofluorescence (nuclei) with CD68-positive cells were evaluated whether they express PARP14 and/or PARP9 (600 cells per sample). The quantification of immunofluorescence was performed by examiners who were blinded to group allocation (macrophage-rich versus BMT PARP14+/−/−LDR−/+− and BMT PARP14+/−/−LDR−/−−− mice). No randomization method was used.

### RNA interference

RNA silencing was performed as described previously. Briefly, 20 nmol l−1 siRNA against PARP14 (L-023583 for human cells and L-160447 for mouse cells) and PARP9 (L-014734 for human cells) were transfected by manual transfection in at least three sequences of three different levels with 100 μm interval in each animal (n = 5), using the Elements 3.2 software (Nikon). The quantification of histology and immunohistochemistry was performed by examiners who were blinded to group allocation (PARP14+/−/−LDR−/−−− versus PARP14+/−/−LDR−/−−− and BMT PARP14+/−/−LDR−/−−− mice). These mice were fed a high-fat and high-cholesterol diet for 16 weeks after bone marrow reconstitution, and tissues were harvested for histological and molecular analyses.

### Evaluation of arterial lesions

The collected tissue was embedded in OCT compound (Tissue-Tek) and then frozen in liquid nitrogen and stored at −80 °C until further use. Intima and media area and their ratio in injured femoral arteries were measured by manual tracing in at least three sections of three different levels with 100 μm interval in each animal (n = 5), using the Elements 3.2 software (Nikon). The quantification of histology and immunohistochemistry was performed by examiners who were blinded to group allocation (PARP14+/−/−LDR−/−−− versus PARP14+/−/−LDR−/−−− and BMT PARP14+/−/−LDR−/−−− mice).

### Human tissue and counting

PARP14+/−PARP9-positive macrophages. Atherosclerotic carotid arteries (n = 10) were collected from patients undergoing endarterectomy procedures at Brigham and Women’s Hospital according to IRB protocol # 1999P001348 (PL). Informed consent was not necessary because all samples are considered as ‘discarded material’. Samples have two groups, such as macrophage-rich (n = 5) and macrophage-poor (n = 5) plaques, respectively. Samples were included in optimal cutting temperature (OCT) compound and stored at −80 °C until use. In three different fields of each sample (n = 5), 200 cells (nuclei) with CD68-positive cells were evaluated whether they express PARP14 and/or PARP9 (600 cells per sample). The quantification of immunofluorescence was performed by examiners who were blinded to group allocation (macrophage-rich versus no plaque).

### Animal ethics

All animal experiments used in this study were approved by and performed in compliance with Beth Israel Deaconess Medical Center’s Institutional Animal Care and Use Committee (Protocol 024-2014).

### PARP14−/− mice.

PARP14−/− mice were backcrossed into the C57BL/6 genetic background over 10 generations. Male PARP14−/− mice and age-matched PARP14+/+ mice were used for a vascular injury model or as donors for BMT.

### Wire-induced acute vascular injury

Transluminal arterial injury was induced for 10-week-old mice by inserting spring wire (0.38 mm in diameter, C-SF-15-15, Cook) into the femoral artery under microscopic observation (leica M80)55. Right common femoral artery, superficial femoral artery and deep femoral artery (DFA) were first exposed. After loopsing SFA with 9-0 nylon suture, a small hole in the DFA was made and a wire was inserted through the hole and advanced to the iliac artery (10 mm). DFA was ligated with 9-0 nylon suture when the wire was removed at the closer point to DFA and common femoral artery bifurcation than the hole.

### Bone marrow reconstitution

Bone marrow was reconstituted as described previously with minor modifications. Briefly, recipient mice were lethally irradiated with a total dose of 1,000 rads. The next day, unfractionated bone marrow cells (BMCS, 1 × 107) that had been harvested from donor mice and enriched with 0.3 ml of phosphate-buffered saline were administered to each recipient mouse via the tail vein. We confirmed bone marrow reconstitution by examining gene expression of PARP14 in the bone marrow of BMT PARP14+/−/+ and BMT PARP14+/−/+ mice (93.3% reduction of the PARP14 gene in BMT PARP14+/−/+ compared with BMT PARP14+/−/−+ + mice). Four weeks after bone marrow reconstitution, wire-mediated femoral artery injury was performed. Two weeks after injury, to collect arterial samples, mice were killed by intraperitoneal administration of an overdose of Pentobarbital and then perfused with 0.9% NaCl solution at a constant pressure via the left ventricle.

### High-fat diet-induced chronic atherosclerosis

First, we examined PARP9 and PARP14 expression in Apolipoprotein E-deficient (ApoE−/−) mice, which were backcrossed with C57BL/6 mice over 10 generations and then fed by high-fat and high-cholesterol diet for 20 weeks. As a chronic atherosclerosis model, we used low-density lipoprotein receptor (LDLR)-deficient mice (LDLR−/−) fed a high-fat and high-cholesterol diet for 16 weeks. Bone marrow of PARP14−/− or sex and age-matched PARP14+/+ mice was transplanted to lethally irradiated LDR−/−−− mice, as described above (BMT PARP14+/−/−LDR−/−−− and BMT PARP14+/−/−LDR−/−−−−− mice). These mice were fed a high-fat and high-cholesterol diet for 16 weeks after bone marrow reconstitution, and tissues were harvested for histological and molecular analyses.
Nitrate quantification. Nitrate was measured using the Nitrate-Rapid Test Kit (Quick Test Co.) following the manufacturer's instructions. The samples were measured spectrophotometrically at 540 nm.

Flow cytometry. The spleens were isolated, and single-cell suspensions were removed from the spleens by gentle teasing through a 70-μm cell strainer. The cells were stained with anti-CD11c, anti-F4/80, and anti-CD16/32 antibodies (all from BioLegend) and analyzed using a FACSCanto II (BD Biosciences) flow cytometer.

Single-cell gene expression analysis. Single-cell gene expression data were analyzed using the R package Seurat (v3.1.2). The raw counts were normalized using the Trim-mean method (TMM) and log-transformed. The gene expression data were then corrected for technical variation using the Variance Stabilizing Transformation (VST).

NATURE COMMUNICATIONS | DOI: 10.1038/s41467-019-13420-5 ARTICLE

LCM and RNA amplification. LCM was performed on the Leica LMD6500 Microdissection System. The nuclei were cut using the Leica LCM parameters: power: 50 mW; pulse duration: 2 μs; and spot size: 20 μm. RNA was isolated using the Qiagen RNeasy Micro Kit.

Western blot analysis. Western blot analysis was performed using antibodies against rabbit phospho-STAT1 (Cell Signaling), rabbit PARP14 (OriGene Technologies Inc.), and rabbit PARP9 (OriGene Technologies Inc.). The membranes were probed with horseradish peroxidase-conjugated secondary antibodies and developed using the ECL chemiluminescent detection system (GE Healthcare).

ELISA. The ELISA was performed using the Bio-Plex Pro cell signaling multiplex kit (Bio-Rad). The samples were analyzed using the Bio-Plex Pro Reader and the Bio-Plex Pro Manager software.

NITRATE COMMUNICATIONS | DOI: 10.1038/s41467-019-13420-5 ARTICLE
comparisons were performed using a Student’s t-test (GraphPad Prism 5, Prism Software Inc. (La Jolla, CA)). If F test showed the variance was significantly different, an unpaired t-test with Welch’s correction was performed. Exclusion criteria were set by Grubbs’ test. The experiments were not randomized. No statistical method was used to predetermine sample size. The experiments were not randomized.

Data availability. The data that support the findings of this study are available within the article and its Supplementary Information Files.

References
1. Writing Group Members et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 121, e46–e215 (2010).
2. Moran, A. E. et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation 129, 1493–1501 (2014).
3. Glass, C. K. & Witztum, J. L. Atherosclerosis. the road ahead. Cell 104, 503–516 (2001).
4. Liang, C. P., Han, S., Senokuchi, T. & Tall, A. R. The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ. Res. 100, 1546–1555 (2007).
5. Randolph, G. J. Mechanisms that regulate macrophage burden in atherosclerosis. Circ. Res. 114, 1757–1771 (2014).
6. Tabas, I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10, 36–46 (2010).
7. Aikawa, M. & Libby, P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc. Pathol. 13, 125–138 (2004).
8. Ridker, P. M. & Luscher, T. F. Anti-inflammatory therapies for cardiovascular disease. Eur. Heart J. 35, 1782–1791 (2014).
9. Glass, C. K. & Olefsky, J. M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15, 635–645 (2012).
10. Gregor, M. F. & Hotamisligil, G. S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29, 415–445 (2011).
11. Fredman, G., Ozcan, L. & Tabas, I. Common therapeutic targets in cardiometabolic disease. Sci. Transl. Med. 6, 239ps235 (2014).
12. Fukuda, D. et al. Notch ligand Delta-like 4 blockade attenuates atherosclerosis and metabolic disorders. Proc. Natl Acad. Sci. USA 109, E1868–E1877 (2012).
13. Aikawa, M. et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses APOE-related protein expression in human monocyte-derived macrophages. J. Biol. Chem. 285, 525–531 (2010).
14. Lee, I., Blom, U. M., Wang, P. I., Shim, J. E. & Marcotte, E. M. Prioritizing candidate disease genes by network-based boosting of genome-wide association data. Genome Res. 21, 1109–1121 (2011).
15. Dayon, L. et al. Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. Anal. Chem. 80, 2921–2931 (2008).
16. Chris Fraley, An E. R. Model-based clustering, discriminant analysis, and density estimation. J. Am. Stat. Assoc. 97, 611–631 (2002).
17. Ricchiuto, P. et al. mLMV-visHTS: a novel method for multiplexing isobaric mass tagged datasets with an accompanying visualization high throughput screening tool for protein profiling. J. Proteomics 128, 132–140 (2015).
18. Kirchner, M. et al. Computational protein profile similarity screening for quantitative mass spectrometry experiments. Bioinformatics 26, 77–83 (2010).
19. Lee, I., Blom, U. M., Wang, P. I., Shim, J. E. & Marcotte, E. M. Prioritizing candidate disease genes by network-based boosting of genome-wide association data. Genome Res. 21, 1109–1121 (2011).
20. Kall, L., Storey, D. J., MacCoss, M. J. & Noble, W. S. Assigning significance to peptides identified by tandem mass spectrometry using decoy databases. J. Proteome Res. 7, 29–34 (2008).
21. Sharma, A. et al. A disease module in the interactome explains disease heterogeneity, drug response and captures novel pathways and genes in asthma. Hum. Mol. Genet. 24, 3005–3020 (2015).
22. Menche, J. et al. Disease networks. uncovering disease-disease relationships through the incomplete interactome. Science 347, 1257601 (2015).
23. Li, Y. et al. Mitogen-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenosine/uridine-rich element. Mol. Cell Biol. 26, 2399–2407 (2006).
24. Mehrotra, P. et al. Poly (ADP-ribose) polymerase 14 and its enzyme activity regulates T(H)2 differentiation and allergic airway disease. J. Allergy Clin. Immunol. 131, 521–531 e521-512 (2013).
25. Iwata, H. et al. Bone marrow-derived cells contribute to vascular inflammation but do not differentiate into smooth muscle cell lineages. Circulation 122, 2048–2057 (2010).
26. Sata, M. et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat. Med. 8, 403–409 (2002).
27. Sata, M. et al. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. FASEB J. 15, 2530–2532 (2001).
Acknowledgements
This study was supported by a research grant from Kowa Company, Ltd (to M.A.) and
the National Institutes of Health grants R01HL107550 and R01HL126901 (to M.A.). E.A.
was supported by R01HL109506 and R01HL14805. We thank Dr Peter Libby for
providing human specimens, and acknowledge his National Institutes of Health grant
R01HL080472, which supported his tissue core. We also thank Mr Tyler S. Faits and Mr
Dhruv Desai for their technical assistance, and Ms Chelsea Swallom for her editorial
expertise.

Author contributions
H.I. took a leading role in this study and contributed to study design, sample prepara-
tions and data analysis of proteomic screening, performance of various in vitro and
in vivo validation experiments and drafting the manuscript; C.G. participated in
mechanistic in vitro experiments and analyses of bone marrow chimera; A.S. and A.H.
played a key role in network analysis on the PARP9–PARP14 interactome and human
disease gene modules; P.R. performed bioinformatic analyses in proteomics and systems
biology; W.W.B.G. performed bioinformatic analyses on single-cell gene profiling and
participated in discussions on network analysis; H.Y., T.H. and N.I. participated in
in vitro experiments, particularly ADP-ribosylation assays; I.Y. contributed to ADP-
ribosylation assay by LC-MS/MS; A.M. performed qPCR, western blotting and single-cell
gene profiling; D.F. optimized the conditions for IFN-γ- and IL-4-stimulated macrophage
cultures; M.B. helped to interpret in vitro and in vivo data and provided PARP14−/−
mice and the mutant STAT1 construct; A.-L.B. provided insight into network analysis;
E.A. directs the histopathology laboratory in our centre and contributed to histomor-
phological analysis on human and mouse atherosclerotic plaques; S.A.S. directs the
proteomics research laboratory in our centre and took a leadership role in mass spec-
trometry-based proteomics and ADP-ribosylation assays; and M.A. initiated and directed
the study, obtained funding and contributed to in vitro and in vivo study design, data
interpretations, drafting and finalizing the manuscript and overall administration.

Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications

Competing financial interests: The authors declare no competing financial
interests.

Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/

How to cite this article: Iwata, H. et al. PARP9 and PARP14 cross-regulate
macrophage activation via STAT1 ADP-ribosylation. Nat. Commun. 7, 12849
doi: 10.1038/ncomms12849 (2016).

This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016